Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Cancer Cell

Journal
uri icon
  • Overview
  • Identity
  • View All
scroll to property group menus

Overview

articles

  • Intratumor heterogeneity: The Rosetta Stone of therapy resistance.  37:471-484. 2020
  • Therapeutic targeting of CDK12/CDK13 in triple-negative breast cancer.  36:545-558. 2019
  • Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.  35:916-931. 2019
  • Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting.  35:489-503. 2019
  • NRF2 and the hallmarks of cancer.  34:21-43. 2018
  • EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma.  33:202-216. 2018
  • Employing metabolism to improve the diagnosis and treatment of pancreatic cancer.  31:5-19. 2017
  • MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer.  32:71-87. 2017
  • An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers.  30:683-693. 2016
  • EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis.  30:197-213. 2016
  • A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy.  29:117-129. 2016
  • Targeting aberrant epigenetic networks mediated by PRMT1 and KDM4C in acute myeloid leukemia.  29:32. 2016
  • Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia.  28:343-356. 2015
  • Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis.  28:42-56. 2015
  • Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.  27:644-657. 2015
  • Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.  27:327-341. 2015
  • MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.  25:469-483. 2014
  • Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.  25:516-529. 2014
  • The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity.  23:332-346. 2013
  • Platelets alter tumor cell attributes to propel metastasis: programming in transit.  20:553-554. 2011
  • An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.  20:384-399. 2011
  • A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions.  19:527-540. 2011
  • A stapled p53 helix overcomes HDMX-mediated suppression of p53.  18:411-422. 2010
  • Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.  18:258-267. 2010
  • Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis.  14:299-311. 2008
  • The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin cd151.  13:221-234. 2008
  • The DARC side of metastasis: shining a light on KAI1-mediated metastasis suppression in the vascular tunnel.  10:177-178. 2006
  • Targeting ornithine decarboxylase in myc-induced lymphomagenesis prevents tumor formation.  7:433-444. 2005
  • Inhibition of NF-kappa B in cancer cells converts inflammation-induced tumor growth mediated by TNF alpha to TRAIL-mediated tumor regression.  6:297-305. 2004
  • Targeted disruption of beta 1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction.  6:159-170. 2004
  • Naturally death-resistant precursor cells revealed as the origin of retinoblastoma.  5:513-515. 2004
  • Puma is an essential mediator of p53-dependent and -independent apoptotic pathways.  4:321-328. 2003
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1535-6108

Electronic International Standard Serial Number (EISSN)

  • 1878-3686

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support